Pharmaceutical company Eli Lilly announced its experimental weight loss drug successfully cleared a crucial obesity trial. The next-generation treatment demonstrated dramatic weight reduction, with some reports indicating results comparable to surgical interventions.
In a study, the experimental shot led to an average body weight reduction of 28%. Individuals participating in the trial reportedly lost up to 85 pounds, according to company statements.
This new drug represents a significant development in the treatment of obesity. This is a developing story and will be updated as details emerge.
